

## Supplementary Information

**Enhancing the anti-tumour activity of  $^{177}\text{Lu}$ -DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP.**


\*Carleen Cullinane<sup>a,c</sup>, \*Kelly Waldeck<sup>a</sup>, Laura Kirby<sup>a</sup>, Buck E Rogers<sup>e</sup>, Peter Eu<sup>b</sup>, Richard W Tothill<sup>a,d</sup> and Rodney J Hicks<sup>a,b,c</sup>

<sup>a</sup>Division of Cancer Research and <sup>b</sup>Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

<sup>c</sup>Sir Peter MacCallum Department of Oncology and <sup>d</sup>Department of Clinical Pathology and Centre for Cancer Research, University of Melbourne, Parkville, Victoria, Australia,

<sup>e</sup>Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO, 63110, USA

Corresponding Author: Carleen Cullinane  
Email: [carleen.cullinane@petermac.org](mailto:carleen.cullinane@petermac.org)  
Phone: +61-3-85597120



**Supplementary Figure S1:**  $^{68}\text{GaTate}$  PET imaging of tumour models *in vivo*. Tumour bearing mice were imaged on a small animal PET scanner at 1 hr post injection with  $^{68}\text{GaTate}$ . Representative maximum intensity projection images are shown for each tumour model. T, tumour; K, kidney; B, bladder.